Clinical Trial Update: Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) [Phase 3]

View source ↗

Summary

This Phase 3 trial compares sacituzumab govitecan plus pembrolizumab to pembrolizumab alone in metastatic non-small cell lung cancer with PD-L1 TPS ≥ 50%. The s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• TRODELVY (sacituzumab govitecan)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Non-small Cell Lung Cancer (NSCLC) | Phase 3 | Status: RECRUITING